期刊
PHARMACOGENOMICS
卷 16, 期 17, 页码 1919-1929出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.136
关键词
BDNF; cytokines; depression; duloxetine; IL-6; inflammation; placebo; treatment response; TSPO
资金
- Canadian Biomarker Integration Network in Depression (CAN-BIND)
Aim: This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression. Patients & methods: Twenty SNPs in IL-1 beta, IL-2, IL-6, TSPO and BDNF were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Asberg Depression Rating Scale. Results: IL-6 variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing. Conclusion: Our findings tentatively suggest that IL-6 variants play a role in duloxetine and placebo response, which warrants further investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据